Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gp100 dna-hvj-liposome vaccine
- Development stage
- Preclinical
- Lead developer
- Osaka University
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The gp100 DNA-HVJ-liposome vaccine is a preclinical cancer vaccine candidate designed to treat melanoma. It consists of a plasmid DNA encoding the human melanoma-associated antigen gp100 (glycoprotein 100) encapsulated within a fusogenic delivery system known as HVJ-AVE liposomes. This delivery vehicle combines the hemagglutinating virus of Japan (HVJ; Sendai virus) with artificial viral envelope (AVE) liposomes to facilitate efficient entry of the DNA into host cells via membrane fusion. Upon administration, the vaccine stimulates the production of gp100-specific antibodies and activates cytotoxic T lymphocytes (CTLs), which target and destroy melanoma cells expressing the gp100 antigen. Research published in 1999 demonstrated that intramuscular injection of this vaccine could induce protective immunity and significantly delay tumor progression in mouse melanoma models.
- Other names
- gp100 DNA-HVJ-AVE liposome vaccinegp-100 DNA-HVJ-AVE liposome vaccinegp 100 DNA-HVJ-AVE liposome vaccinehuman gp100 DNA-HVJ-liposome vaccine
02
Targets
PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on gp100 dna-hvj-liposome vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gp100 dna-hvj-liposome vaccine.